Artificial Intelligence in Lung Cancer

1.Where do you come from?
Hong Kong SAR, ChinaMainland ChinaMacau SAR, ChinaOthers

2.Surname

First name

3.Specialized Areas
Clinical OncologyMedical OncologyRadiology / Radiation OncologyHematology OncologyMedical PhysicsPathologySurgeryPulmonaryOthers

4.Name of Organization (Hospital / Clinic / University):

5.Email :

Contact Information (Email / Mobile / WhatsApp / WeChat / NA):

6.Would you like to become a member of this collaborative event focusing on artificial intelligence (AI) in the future?
YesNoMay be

Survey for online registration – Artificial Intelligence in Lung Cancer
(All inputs will be kept private and confidential.)

Artificial Intelligence

1.What do you think is the most promising application of artificial intelligence in lung cancer management?
Helping to make clinical decisionsRadiotherapy planning and contouringRadiological screening of lung nodulesManaging patient reported symptoms in supportive careAll of aboveOthers

EGFR exon 20 insertion positive non-small cell lung cancer

2.Do you routinely conduct EGFR exon 20 insertion (ex20ins) biomarker testing in advanced (stage IV) NSCLC patients?
YesNoIf the patient can afford

3.Which test do you firstly use for EGFR ex20ins mutation NSCLC?
NGS (next generation sequencing)PCROthers

4.Which therapy do you use primarily for EGFR ex20ins mutation NSCLC?
ChemotherapyEGFR TKIImmunotherapyCombined chemotherapy and immunotherapyCombined chemotherapy and anti-VEGFCombined chemotherapy, anti-VEGF and immunotherapyOthers

ALK fusion positive non-small cell lung cancer

5.What is the most important consideration for choosing amongst the different first line ALK TKI options currently available?
Progression free survivalOverall response rateOverall survivalIntracranial efficacyQuality of lifeSide effect profile

6.Are acquired ALK mutations information essential for making your treatment decision in second line therapy?
YesNo